WORCESTER, Mass.--(BUSINESS WIRE)--The joint venture between Advanced Cell Technology, Inc. (OTC:ACTC) and leading Korean-based biotechnology company CHA Biotech Co, Ltd. (CHA), announced today that the company would be named “Stem Cell & Regenerative Medicine International.”